Anti-PD-1/PD-L1 therapy combined with
chemotherapy/antiangiogenic therapy for EGFR-mutated lung cancer
patients: a retrospective analysis
Ran Hu1*, Zhiting Zhao1*, Yue
Shi1, Meiqi Shi1, Guohao
Xia1, Shaorong Yu1, Jifeng
Feng1
Department of Medical Oncology, The Affiliated Cancer Hospital of
Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu
Institute of Cancer Research, Nanjing, Jiangsu Province, China.
* These authors have contributed equally to this work.
Corresponding author: Shaorong Yu, email:yushaorong2009@163.com;Jifeng Feng, email:jifeng_feng@163.comaddress: Baiziting No.42, Nanjing, Jiangsu Province, China, 210009.
Conflict of Interest : None.
Acknowledgments : None.
Keywords : EGFR, mutation, lung adenocarcinoma, PD-1,
chemotherapy